Brian Busey and Maryrose McLaughlin authored an article for Law360 titled, “What's At Play In Rising Lanham Act Cases At The ITC.” They reviewed recent false advertising cases involving medical-related products, explores possible limits on such claims under the Federal Food, Drug, and Cosmetic Act, and outlines practical issues practitioners face in bringing and defending such cases at the U.S. International Trade Commission (ITC).
Read the full article.
ITC Resource Center